콘텐츠로 건너뛰기
Merck

RBPJ is a novel target for rhabdomyosarcoma therapy.

PloS one (2012-07-14)
Hiroko Nagao, Takao Setoguchi, Sho Kitamoto, Yasuhiro Ishidou, Satoshi Nagano, Masahiro Yokouchi, Masahiko Abematsu, Naoya Kawabata, Shingo Maeda, Suguru Yonezawa, Setsuro Komiya
초록

The Notch pathway regulates a broad spectrum of cell fate decisions and differentiation processes during fetal and postnatal development. In addition, the Notch pathway plays an important role in controlling tumorigenesis. However, the role of RBPJ, a transcription factor in the Notch pathway, in the development of tumors is largely unknown. In this study, we focused on the role of RBPJ in the pathogenesis of rhabdomyosarcoma (RMS). Our data showed that Notch pathway genes were upregulated and activated in human RMS cell lines and patient samples. Inhibition of the Notch pathway by a γ-secretase inhibitor (GSI) decreased the in vitro proliferation of RMS cells. Knockdown of RBPJ expression by RNAi inhibited the anchorage-independent growth of RMS cells and the growth of xenografts in vivo. Additionally, overexpression of RBPJ promoted the anchorage-independent growth of RMS cells. Further, we revealed that RBPJ regulated the cell cycle in RMS xenograft tumors and decreased proliferation. Our findings suggest that RBPJ regulates the RMS growth, and that the inhibition of RBPJ may be an effective therapeutic approach for patients with RMS.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
MISSION® esiRNA, targeting mouse Rbpj